Vertex Pharmaceuticals (VRTX) Net Margin (2009 - 2026)
Vertex Pharmaceuticals' (VRTX) quarterly Net Margin came in at 34.53% in Q1 2026, up 1120.0% year-on-year from 2.83% in Q1 2025, and down 7.52% quarter-over-quarter from 37.34% in Q4 2025.
Vertex Pharmaceuticals (VRTX) Net Margin (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Net Margin history runs 17 years deep, the most recent figure standing at 34.53% for Q1 2026.
- On a quarterly basis, Net Margin rose 1120.0% year-over-year to 34.53% in Q1 2026; TTM through Mar 2026 was 35.51%, a 4442.0% increase from a year earlier, with the FY2025 full-year figure at 32.94%, up 3780.0% from the prior year.
- Net Margin slipped to 34.53% in Q1 2026 per VRTX's latest filing, from 37.34% in the prior quarter.
- Across five years, Net Margin topped out at 41.69% in Q3 2023 and bottomed at 135.83% in Q2 2024.
- The 5-year median for Net Margin is 36.33% (2022), against an average of 25.55%.
- Across the five-year window, Net Margin tumbled 17256 bps in 2024 and soared 17067 bps in 2025, its largest moves.
- Year by year, Net Margin stood at 35.56% in 2022, then advanced by 8 bps to 38.48% in 2023, then fell by 19 bps to 31.35% in 2024, then grew by 19 bps to 37.34% in 2025, then declined by 8 bps to 34.53% in 2026.
- Per Business Quant, the three latest VRTX Net Margin figures stand at 34.53% (Q1 2026), 37.34% (Q4 2025), and 35.2% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 17.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.53% |
| Dec 31, 2025 | 37.34% |
| Sep 30, 2025 | 35.20% |
| Jun 30, 2025 | 34.84% |
| Mar 31, 2025 | 23.33% |
| Dec 31, 2024 | 31.35% |
| Sep 30, 2024 | 37.71% |
| Jun 30, 2024 | -135.83% |
| Mar 31, 2024 | 40.87% |
| Dec 31, 2023 | 38.48% |
| Sep 30, 2023 | 41.69% |
| Jun 30, 2023 | 36.73% |
| Mar 31, 2023 | 29.47% |
| Dec 31, 2022 | 35.56% |
| Sep 30, 2022 | 39.86% |
| Jun 30, 2022 | 36.90% |
| Mar 31, 2022 | 36.33% |
| Dec 31, 2021 | 37.16% |
| Sep 30, 2021 | 42.94% |
| Jun 30, 2021 | 3.74% |